Sanofi Pasteur, has announced that the FDA has approved the supplemental biologics license application (sBLA) for licensure of its four-strain...
The FDA has approved a supplemental Biologics License Application for Fluzone High-Dose Quadrivalent (Influenza Vaccine), from Sanofi, for use in...
The FDA has approved the 0.5mL dose of its influenza vaccine, Fluzone Quadrivalent, from Sanofi Pasteur, for treating children falling...
Novavax, Inc., announced publication of complete results from a pivotal Phase III clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M adjuvant, in The Lancet Infectious Diseases (Lancet ID).
The FDA has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (vaccine), from Sanofi, to include efficacy data...
Sanofi Pasteur, the vaccines division of Sanofi announced that The New England Journal of Medicine published positive results from a...
The FDA has approved Fluarix Quadrivalent Influenza Virus Vaccine from Glaxo Smith Kline, for the immunisation of children (three years...
The FDA has approved FluMist Quadrivalent,from Medimmune a vaccine to prevent seasonal influenza in people ages 2 years through 49...
Glaxo Smith Kline has recalled doses of its FluLaval Quadrivalent flu vaccine due to effectiveness problems. GSK has announced that...